- Home
- CTMX vs BEAT Comparison
CTMX vs BEAT Comparison
Compare CTMX & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- BEAT
- Stock Information
- Founded
- CTMX 2008
- BEAT 2015
- Country
- CTMX United States
- BEAT United States
- Employees
- CTMX N/A
- BEAT N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- CTMX Health Care
- BEAT Technology
- Exchange
- CTMX Nasdaq
- BEAT Nasdaq
- Market Cap
- CTMX 89.1M
- BEAT 74.4M
- IPO Year
- CTMX 2015
- BEAT 2021
- Fundamental
- Price
- CTMX $0.89
- BEAT $2.79
- Analyst Decision
- CTMX Buy
- BEAT Buy
- Analyst Count
- CTMX 6
- BEAT 1
- Target Price
- CTMX $5.77
- BEAT $8.00
- AVG Volume (30 Days)
- CTMX 1.1M
- BEAT 107.1K
- Earning Date
- CTMX 11-07-2024
- BEAT 11-07-2024
- Dividend Yield
- CTMX N/A
- BEAT N/A
- EPS Growth
- CTMX N/A
- BEAT N/A
- EPS
- CTMX 0.16
- BEAT N/A
- Revenue
- CTMX $126,617,000.00
- BEAT N/A
- Revenue This Year
- CTMX $11.79
- BEAT N/A
- Revenue Next Year
- CTMX N/A
- BEAT N/A
- P/E Ratio
- CTMX $5.51
- BEAT N/A
- Revenue Growth
- CTMX 33.66
- BEAT N/A
- 52 Week Low
- CTMX $0.83
- BEAT $1.06
- 52 Week High
- CTMX $5.85
- BEAT $3.39
- Technical
- Relative Strength Index (RSI)
- CTMX 35.66
- BEAT 64.00
- Support Level
- CTMX $0.84
- BEAT $2.33
- Resistance Level
- CTMX $1.08
- BEAT $3.11
- Average True Range (ATR)
- CTMX 0.07
- BEAT 0.22
- MACD
- CTMX -0.01
- BEAT 0.04
- Stochastic Oscillator
- CTMX 17.43
- BEAT 64.04
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.